TherapeuticsMD, Inc. (NASDAQ:TXMD) Director Tommy G. Thompson bought 5,000 shares of the firm’s stock in a transaction dated Friday, December 8th. The stock was purchased at an average price of $6.21 per share, with a total value of $31,050.00. Following the transaction, the director now owns 3,555 shares in the company, valued at approximately $22,076.55. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

TherapeuticsMD, Inc. (NASDAQ TXMD) traded up $0.16 during trading hours on Monday, reaching $6.42. The company had a trading volume of 2,934,758 shares, compared to its average volume of 2,891,053. TherapeuticsMD, Inc. has a twelve month low of $3.50 and a twelve month high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The business had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million. During the same quarter in the previous year, the firm posted ($0.13) EPS. The business’s revenue for the quarter was down 19.7% compared to the same quarter last year. equities analysts forecast that TherapeuticsMD, Inc. will post -0.37 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in TXMD. Amalgamated Bank boosted its position in TherapeuticsMD by 7.2% during the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after acquiring an additional 1,322 shares during the period. Principal Financial Group Inc. boosted its position in TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after acquiring an additional 818 shares during the period. Virtu KCG Holdings LLC acquired a new position in TherapeuticsMD during the 2nd quarter worth $157,000. Quantbot Technologies LP acquired a new position in TherapeuticsMD during the 3rd quarter worth $189,000. Finally, Cetera Investment Advisers acquired a new position in TherapeuticsMD during the 2nd quarter worth $214,000. Institutional investors own 73.76% of the company’s stock.

Several brokerages have recently commented on TXMD. Morgan Stanley began coverage on TherapeuticsMD in a research report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 target price for the company. BidaskClub upgraded TherapeuticsMD from a “hold” rating to a “buy” rating in a research report on Friday, September 8th. Jefferies Group restated a “buy” rating and set a $15.00 price objective on shares of TherapeuticsMD in a research report on Friday, September 8th. Deutsche Bank restated a “buy” rating and set a $10.00 price objective on shares of TherapeuticsMD in a research report on Wednesday, September 13th. Finally, Cowen restated an “outperform” rating and set a $16.00 price objective (up previously from $13.00) on shares of TherapeuticsMD in a research report on Monday, November 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $15.00.

COPYRIGHT VIOLATION WARNING: “TherapeuticsMD, Inc. (TXMD) Director Purchases $31,050.00 in Stock” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/therapeuticsmd-inc-txmd-director-purchases-31050-00-in-stock/1758092.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.